This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Nov 2;360(9343):1430.

doi: 10.1016/S0140-6736(02)11388-2.

Second-line treatment for chronic tuberculosis

Prasanta R Mohapatra, Ashok K Janmeja, Varinder Saini, Suman K Das, Anirban Deb

PMID: 12424025
DOI: 10.1016/S0140-6736(02)11388-2

Comment

Second-line treatment for chronic tuberculosis

Prasanta R Mohapatra et al. Lancet. 2002.

. 2002 Nov 2;360(9343):1430.

doi: 10.1016/S0140-6736(02)11388-2.

Authors

Prasanta R Mohapatra, Ashok K Janmeja, Varinder Saini, Suman K Das, Anirban Deb

PMID: 12424025
DOI: 10.1016/S0140-6736(02)11388-2

No abstract available

PubMed Disclaimer

Comment on

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA. Suárez PG, et al. Lancet. 2002 Jun 8;359(9322):1980-9. doi: 10.1016/S0140-6736(02)08830-X. Lancet. 2002. PMID: 12076553

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science